Quatrx Pharmaceuticals, a developer of drugs in the endocrine, metabolic and cardiovascular therapeutic areas, plans to offer 6.0 million shares at a range of $11 to $13. Assuming the stock prices at the midpoint, the company will have an initial market capitalization of $245 million. Banc of America and Cowen & Co. are the joint book runners on the deal. Timing has yet to be announced.
IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
